- Home
- CEP vs BDSX Comparison
CEP vs BDSX Comparison
Compare CEP & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEP
- BDSX
- Stock Information
- Founded
- CEP 2020
- BDSX 2005
- Country
- CEP United States
- BDSX United States
- Employees
- CEP N/A
- BDSX N/A
- Industry
- CEP
- BDSX Precision Instruments
- Sector
- CEP
- BDSX Health Care
- Exchange
- CEP NYSE
- BDSX Nasdaq
- Market Cap
- CEP 131.6M
- BDSX 115.4M
- IPO Year
- CEP 2024
- BDSX 2020
- Fundamental
- Price
- CEP $10.60
- BDSX $0.55
- Analyst Decision
- CEP
- BDSX Strong Buy
- Analyst Count
- CEP 0
- BDSX 3
- Target Price
- CEP N/A
- BDSX $2.93
- AVG Volume (30 Days)
- CEP 30.9K
- BDSX 341.6K
- Earning Date
- CEP 01-01-0001
- BDSX 05-07-2025
- Dividend Yield
- CEP N/A
- BDSX N/A
- EPS Growth
- CEP N/A
- BDSX N/A
- EPS
- CEP 0.24
- BDSX N/A
- Revenue
- CEP N/A
- BDSX $71,323,000.00
- Revenue This Year
- CEP N/A
- BDSX $32.90
- Revenue Next Year
- CEP N/A
- BDSX $24.65
- P/E Ratio
- CEP $44.39
- BDSX N/A
- Revenue Growth
- CEP N/A
- BDSX 45.30
- 52 Week Low
- CEP $9.99
- BDSX $0.51
- 52 Week High
- CEP $10.95
- BDSX $2.04
- Technical
- Relative Strength Index (RSI)
- CEP N/A
- BDSX 35.73
- Support Level
- CEP N/A
- BDSX $0.53
- Resistance Level
- CEP N/A
- BDSX $0.65
- Average True Range (ATR)
- CEP 0.00
- BDSX 0.07
- MACD
- CEP 0.00
- BDSX 0.00
- Stochastic Oscillator
- CEP 0.00
- BDSX 15.97
About CEP CANTOR EQUITY PARTNERS INC
Cantor Equity Partners Inc is a blank check company.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.